The use of toxicokinetic data in preclinical safety assessment: A toxicologic pathologist perspective

被引：10
|
作者：
Ploemen, Jan-Peter H. T. M.
Kramer, Hester
Krajnc, Erno I.
Martin, Iain
机构：
[1] Organon, Dept Toxicol & Drug Disposit, NL-5340 BH Oss, Netherlands
[2] Organon, Clin Pharmacol & Kinet, NL-5340 BH Oss, Netherlands
[3] Organon Res, Dept Pharmacol, Oss, Scotland
来源：
TOXICOLOGIC PATHOLOGY | 2007年 / 35卷 / 06期
关键词：
pharmacokinetics; drug development; risk assessment; toxicokinetics; toxicological pathology;
D O I：
10.1080/01926230701584247
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
Collection of toxicokinetic data has become a routine practice during the last 15 years in most general toxicity studies on pharma. It enables the correlation of pathological changes with the plasma concentration of drugs and/or their metabolites. This overview summarizes the use of the toxicokinetic data from the perspective of the toxicologic pathologist.
引用
收藏
页码：834 / 837
页数：4
相关论文
共 50 条
  • [1] The role of the toxicologic pathologist in the preclinical safety evaluation of biotechnology-derived pharmaceuticals
    Pilling, AM
    [J]. TOXICOLOGIC PATHOLOGY, 1999, 27 (06) : 678 - 688
  • [2] The use of toxicokinetic and toxicodynamic data in risk assessment: an international perspective
    Gundert-Remy, U
    Sonich-Mullin, C
    [J]. SCIENCE OF THE TOTAL ENVIRONMENT, 2002, 288 (1-2) : 3 - 11
  • [3] Apoptosis in the kidney: A toxicologic pathologist's perspective
    Short, BG
    [J]. TOXICOLOGIC PATHOLOGY, 1998, 26 (06) : 826 - 827
  • [4] Use of toxicokinetic data in bioaccumulation assessment
    Thies, J. Peltola
    Lantto, T. A.
    Lapenna, S.
    Muller, G.
    Kloslova, Z.
    Caley, J.
    Andersen, S.
    Gudbrandsen, M.
    Hofer, T.
    Myhre, O.
    Verbruggen, E.
    Lepper, P.
    [J]. TOXICOLOGY LETTERS, 2016, 258 : S226 - S226
  • [5] Perspectives of data science in preclinical safety assessment
    Steger-Hartmann, Thomas
    Kreuchwig, Annika
    Wang, Ken
    Birzele, Fabian
    Draganov, Dragomir
    Gaudio, Stefano
    Rothfuss, Andreas
    [J]. DRUG DISCOVERY TODAY, 2023, 28 (08)
  • [6] Preclinical Evaluation of Mesh Implants: The Pathologist's Perspective
    Keating, John H.
    Melidone, Raffaele
    Garcia-Polite, Fernando
    [J]. TOXICOLOGIC PATHOLOGY, 2019, 47 (03) : 379 - 389
  • [7] Antisense Oligonucleotide Therapies: The Promise and the Challenges from a Toxicologic Pathologist's Perspective
    Frazier, Kendall S.
    [J]. TOXICOLOGIC PATHOLOGY, 2015, 43 (01) : 78 - 89
  • [8] Toxicologic Pathology: Nonclinical Safety Assessment
    Francke, Sabine
    [J]. TOXICOLOGIC PATHOLOGY, 2015, 43 (05) : 747 - 748
  • [9] THOUGHTS ON THE PROPER USE AND INTERPRETATION OF CLINICAL PATHOLOGY DATA IN PRECLINICAL SAFETY TESTING - A CANADIAN PERSPECTIVE
    MUELLER, RW
    [J]. TOXICOLOGIC PATHOLOGY, 1992, 20 (03) : 526 - 527
  • [10] Innovative strategies for agrochemical safety assessments: Use of toxicokinetic data for Arylex™ and Rinskor™
    Aggarwal, M.
    Papineni, S.
    Terry, C.
    Rasoulpour, R.
    Murphy, L.
    Bartels, M.
    [J]. TOXICOLOGY LETTERS, 2016, 258 : S227 - S227
12345